RE:This IPF clinical trial is doing pretty good Looks like Sky has found a competitor's trial (Promedior - even the name is similar - hmmm - coincidence? - just saying). They are a private company, started in 2006, but they only have a couple of fibrosis target indications (including IPF). And they appear to be a little bit behind us regarding IPF.
They key thing to note is that they received $150 million up front with a total possible payout of $1.25 billion from Bristol-Myers - for 2 fibrosis indications only !!!
So they get that deal for early/intermediate clinical trial results & Intermune was bought out 'in desperation' for $8.3 billion by Roche.
What the f**K does that say about the potential value of PBI-4050 for PROMETIC-PLI ??!!!!??!!!!!!! :0 One can only dream & wonder, hopefully it becomes reality soon !!
Sky: I'm not sure if you knew it was Promedior & not Prometic (I'll assume you werent trying to find negative info to 'try to influence' the SP negatively in the short-term).
Seriously Sky, this info is good to know. Because of this, now I know about their upfront & milestone payments & what it could imply for PLI !!
Good luck to all longs! :)